Found 4337 clinical trials
Quantifying Oxygen Utilization of Tumors Using Oxygen-Enhanced Molecular MRI
By using the oxygen-enhanced molecular MRI, researchers will be able to create spatial "maps" depicting areas of abnormal oxygen utilization unique to cancer. This type of information may be useful for diagnosing new cancers, understanding various "subtypes" of cancer that might utilize oxygen differently, or this information may be useful …
- 0 views
- 19 Feb, 2024
- 1 location
SBRT for Breast Cancer Oligometastases
Response and progression for these metastases will be evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions is used in the RECIST criteria.
- 0 views
- 19 Feb, 2024
- 1 location
Phase I Study in Advanced Malignancies
The doses of radiation administered in this study will be lower than those typically used to treat cancer. However, with administration of ALA, which has been shown to be selectively concentrated in neoplastic cells, it is reasonable to expect responses in the target lesion(s) with relative sparing of nearby normal …
- 0 views
- 19 Feb, 2024
- 1 location
A Study to Assess the Safety Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114.
- 0 views
- 19 Feb, 2024
- 4 locations
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
This is a Phase 1, multicenter, open-label, multiple-dose, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, and pharmacodynamics of TTX-080 monotherapy in subjects with advanced or metastatic solid tumors known to express HLA-G. This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and preliminary antitumor …
- 0 views
- 19 Feb, 2024
- 2 locations
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer …
- 0 views
- 19 Feb, 2024
- 10 locations
Evaluation of a Oncology Day Care Unit Programme With Two Different Focuses
The aim of this study is to investigate the effects of a nature-centred integrative oncology day care unit programme ("outdoor concept") compared with an already established integrative oncology day care unit programme ("indoor concept").
- 0 views
- 19 Feb, 2024
- 1 location
Tumor Electric Fields Treatment System for Glioblastoma
This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.
- 0 views
- 19 Feb, 2024
- 1 location
Pantoprazole in Cisplatin Nephrotoxicity
Pantoprazole in Cisplatin Nephrotoxicity
- 0 views
- 19 Feb, 2024
- 1 location
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).
To determine the maximum tolerated dose(s) (MTD) or the Recommended Dose for Expansion (RDE) and dosing regimen for further development of BI 764532. The MTDs will be defined based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period in studied regimens. The Recommended Dose …
- 0 views
- 19 Feb, 2024
- 1 location